Cite
HARVARD Citation
Metz, H. et al. (n.d.). 712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors. Journal for immunotherapy of cancer. p. A427. [Online].